Literature DB >> 17445591

Challenge of tuberculosis in renal transplantation.

K K Malhotra1.   

Abstract

There is very high incidence of tuberculosis (TB) in dialysis and renal transplant (RT) recipients in developing countries. Clinical manifestation of TB may be atypical or obscure in initial stages. Common clinical abnormalities include pyrexia, pulmonary infiltrates, exudative pleural effusion, and exudative ascites. Aggressive investigations must be done in patients with pyrexia, pulmonary abnormalities, scanty sputum, and weight loss. BAL and computed tomography (CT) scan of the chest should be done in such cases. Tuberculin skin test is not helpful in the majority of patients. New blood tests to quantitate PPD reactivity in vivo and tests to distinguish between latent M tuberculosis infection from BCG-induced reactivity have been devised recently. Side effects of anti-TB drugs, especially hepatitis, need close observation because of the frequent occurrence of viral hepatitis in such cases. Tests to confirm latent TB are desirable before starting chemoprophylaxis in RT recipients. INH prophylaxis cannot be recommended universally in all RT recipients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17445591     DOI: 10.1016/j.transproceed.2007.01.062

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  3 in total

1.  [Preventing post solid organ transplant tuberculosis with antibiotic prophylaxis].

Authors:  L Schneidewind; S Schmidt
Journal:  Urologe A       Date:  2016-02       Impact factor: 0.639

Review 2.  Antibiotic prophylaxis for preventing post solid organ transplant tuberculosis.

Authors:  Bappa Adamu; Aliyu Abdu; Abdullahi A Abba; Musa M Borodo; Imad M Tleyjeh
Journal:  Cochrane Database Syst Rev       Date:  2014-03-04

3.  Mycobacterium tuberculosis infection following kidney transplantation.

Authors:  Karima Boubaker; Tahar Gargah; Ezzedine Abderrahim; Taieb Ben Abdallah; Adel Kheder
Journal:  Biomed Res Int       Date:  2013-10-08       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.